✦ LIBER ✦

Phase II trial of mitoxantrone in patients with hepatocellular carcinoma

✍ Scribed by Yoshida, Takanobu; Okazaki, Nobuo; Yoshino, Masahiro; Ohkura, Hisanao; Miyamoto, Kengo; Shimada, Yasuhiro

Book ID: 122887463
Publisher: Elsevier Science
Year: 1988
Weight: 139 KB
Volume: 24
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(88)90104-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized multicenter phase II clinic

A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma

✍ Qinghua Zhou; Xun Sun; Lingyuan Zeng; Jie Liu; Zhirong Zhang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 151 KB

## From the clinical editor: Intravenous administration of mitoxantrone-loaded polybutylcyanacrylate nanoparticles (dhad-pbca-nps) allows increased cytotoxicity in hepatic tumors and prolonged the median survival periods to 5.46 months compared to 3.23 months in controls.

A phase I-II trial of mitoxantrone by he

A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver

✍ Dennie V. Jones Jr.; Yehuda Z. Patt; Jaffer A. Ajani; James Abbruzzese; Bernard 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 2 views

A phase II trial of gemcitabine in patie

A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma

✍ Charles S. Fuchs; Jeffrey W. Clark; David P. Ryan; Mathew H. Kulke; Haesook Kim; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract ## BACKGROUND There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerabili

Phase II trial of tamoxifen, etoposide,

Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma

✍ Suzanne D. Conzen; Peter A. Kaufman; Christine Arvizu; Paul LeMarbre; L. Herbert 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 554 KB

## BACKGROUND. Based on previous data demonstrating a potentially synergistic interaction between tamoxifen and cisplatin in metastatic melanoma therapy, a Phase I1 study was performed to assess the activity of tamoxifen, etoposide, mitoxantrone, and cisplatin (TEMP) in patients with metastatic br

Thalidomide in the treatment of patients

Thalidomide in the treatment of patients with hepatocellular carcinoma : A Phase II trial

✍ Yehuda Z. Patt; Manal M. Hassan; Richard D. Lozano; Ajay K. Nooka; Isaac I. Schn 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

## Abstract ## BACKGROUND The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents. However, the abundant vascularity of HCC presents an attractive target for antiangiogenic therapy that pote

A Phase II trial of nolatrexed dihydroch

A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma

✍ Keith Stuart; Judy Tessitore; Jeff Rudy; Neil Clendennin; Amanda Johnston 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

## BACKGROUND. Inoperable hepatocellular carcinoma is an incurable malignancy with no accepted standard therapy. Chemotherapy has demonstrated occasional responses and the need is great for a new and effective agent. Therefore the authors conducted this Phase II trial of a novel thymidylate syntha